Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 16Carcinoma, Hepatocellular 11Stomach Neoplasms 6Neoplasms 5Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Myositis 2Lung Neoplasms 2Cholangiocarcinoma 2Vascular Complications 1Sjogren's Syndrome 1Scleroderma, Systemic 1Sarcopenia 1Recurrence 1Rectal Neoplasms 1Plaque, Atherosclerotic 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Metastatic Colorectal Adenocarcinoma 1Melanoma 1Lupus Erythematosus, Systemic 1Lung Diseases, Interstitial 1Liver Neoplasms 1Influenza, Human 1Immune-Related Adverse Events 1Hypersensitivity 1

Interventions

Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Immune-Related Adverse Events × Immune Checkpoint Inhibitors × Clear all
NCT07453342 2026-03-06

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

Peking Union Medical College Hospital

Recruiting
500 enrolled

Immune-Related Adverse Events

Data powered by HemOnc (CC BY 4.0) Colophon âš¡